302 related articles for article (PubMed ID: 37405988)
1. Construction and validation of a novel cuproptosis-mitochondrion prognostic model related with tumor immunity in osteosarcoma.
Feng J; Wang J; Xu Y; Lu F; Zhang J; Han X; Zhang C; Wang G
PLoS One; 2023; 18(7):e0288180. PubMed ID: 37405988
[TBL] [Abstract][Full Text] [Related]
2. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
3. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
4. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
[TBL] [Abstract][Full Text] [Related]
5. Construction of a cuproptosis-related lncRNA signature for predicting prognosis and immune landscape in osteosarcoma patients.
Ni S; Hong J; Li W; Ye M; Li J
Cancer Med; 2023 Feb; 12(4):5009-5024. PubMed ID: 36129020
[TBL] [Abstract][Full Text] [Related]
6. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma.
Yan C; Niu Y; Ma L; Tian L; Ma J
J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876
[TBL] [Abstract][Full Text] [Related]
7. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
Dai L; Zhou P; Lyu L; Jiang S
BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a cuproptosis-related lncRNA model correlated to the cancer-associated fibroblasts enable the prediction prognosis of patients with osteosarcoma.
Wang X; Xie C; Lin L
J Bone Oncol; 2023 Feb; 38():100463. PubMed ID: 36569351
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
10. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
12. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
13. A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer.
Du Y; Jiang W; Hou S; Chen Z; Zhou W
Biomed Res Int; 2023; 2023():3419401. PubMed ID: 36714025
[TBL] [Abstract][Full Text] [Related]
14. Cuproptosis-related gene SERPINE1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer.
Feng L; Li G; Li D; Duan G; Liu J
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10851-10865. PubMed ID: 37318594
[TBL] [Abstract][Full Text] [Related]
15. The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Tumour Immune Analysis in Osteosarcoma.
Jiang J; Chu D; Lai X; Liu L; Tao J
Comput Math Methods Med; 2022; 2022():6314182. PubMed ID: 36388161
[TBL] [Abstract][Full Text] [Related]
16. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
[TBL] [Abstract][Full Text] [Related]
17. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
18. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
Yao Y; Chen H; Lou M; Chen T
Front Genet; 2023; 14():1071694. PubMed ID: 36755576
[No Abstract] [Full Text] [Related]
19. A novel cuproptosis-related prognostic 2-lncRNAs signature in breast cancer.
Xu QT; Wang ZW; Cai MY; Wei JF; Ding Q
Front Pharmacol; 2022; 13():1115608. PubMed ID: 36699089
[No Abstract] [Full Text] [Related]
20. Exploring the immune microenvironment of osteosarcoma through T cell exhaustion-associated gene expression: a study on prognosis prediction.
Zhu J; Yuan J; Arya S; Du Z; Liu X; Jia J
Front Immunol; 2023; 14():1265098. PubMed ID: 38169731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]